TELIGENT, INC. (NASDAQ:TLGT) Files An 8-K Results of Operations and Financial ConditionItem 2.02. Results of Operations and Financial Condition
On August 8, 2017, Teligent, Inc. (the “Company”) issued a press release announcing the Company’s earnings for the second quarter ended June 30, 2017 and certain other information. A copy of the press release is attached hereto as Exhibit 99.1.
The Company will conduct a conference call to review its financial results on August 8, 2017, at 4:30 p.m. Eastern Standard Time.
The information, including Exhibit 99.1, in this Form 8-K is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Form 8-K shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall otherwise be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d)The following exhibits are filed with this Report:
|
ExhibitNo. |
Description |
|
99.1 |
Press release of Teligent, Inc., dated August 8, 2017. |
Teligent, Inc. ExhibitEX-99.1 2 ex991.htm EXHIBIT 99.1 Exhibit Exhibit 99.1 News From Buena,…To view the full exhibit click here
About TELIGENT, INC. (NASDAQ:TLGT)
Teligent, Inc., formerly IGI Laboratories, Inc., is a specialty generic pharmaceutical company. The Company markets and sells generic injectable pharmaceutical products under its own label in the United States and Canada. It provides development, formulation and manufacturing services to the pharmaceutical, over-the-counter (OTC) and cosmetic industries. It has two platforms: developing, manufacturing and marketing a portfolio of generic pharmaceutical products under its own label in topical, injectable, complex and ophthalmic dosage forms, and managing its current contract manufacturing and formulation services business. Its pipeline includes over 30 Abbreviated New Drug Applications filed with the United States Food and Drug Administration for additional pharmaceutical products. It holds additional over 40 product candidates at various stages of its development pipeline, 10 of which are on stability testing.